Abstract
Considering the emergence of highly pathogenic influenza viruses and threat of worldwide pandemics, there is an urgent need to develop broadly-protective influenza vaccines. In this study, we demonstrate the potential of T7 bacteriophage-based nanoparticles with genetically fused ectodomain of influenza A virus M2 protein (T7-M2e) as a candidate universal flu vaccine. Immunization of mice with non-adjuvanted T7-M2e elicited M2e-specific serum antibody responses that were similar in magnitude to those elicited by M2e peptide administered in Freund’s adjuvant. Comparable IgG responses directed against T7 phage capsomers were induced following vaccination with wild type T7 or T7-M2e. T7-M2e immunization induced balanced amounts of IgG1 and IgG2a antibodies and these antibodies specifically recognized native M2 on the surface of influenza A virus-infected mammalian cells. The frequency of IFN-γ-secreting T cells induced by T7-M2e nanoparticles was comparable to those elicited by M2e peptide emulsified in Freund’s adjuvant. Emulsification of T7-M2e nanoparticles in Freund’s adjuvant, however, induced a significantly stronger T cell response. Furthermore, T7-M2e-immunized mice were protected against lethal challenge with an H1N1 or an H3N2 virus, implying the induction of hetero-subtypic immunity in our mouse model. T7-M2e-immunized mice displayed considerable weight loss and had significantly reduced viral load in their lungs compared to controls. We conclude that display of M2e on the surface of T7 phage nanoparticles offers an efficient and economical opportunity to induce cross-protective M2e-based immunity against influenza A.
Highlights
Influenza viruses are responsible for seasonal occurrences of influenza epidemics and infrequent, unpredictable worldwide pandemics
We developed a universal influenza vaccine based on T7 phage nanoparticles displaying M2e (T7M2e)
M2e is Efficiently Displayed on T7-phage Nanoparticles A high titer of T7-M2e phage nanoparticles (1011 pfu/ml) was obtained by infection of E. coli BL21 culture at multiplicity of infection (MOI) = 0.01–0.001 after a few hours of incubation (3–5 h)
Summary
Influenza viruses are responsible for seasonal occurrences of influenza epidemics and infrequent, unpredictable worldwide pandemics. Protection against influenza-associated illness by currently licensed vaccines is well-documented for most age-group This protection relies on a close antigenic match between the HA present in the vaccine strains and that of the virus strains circulating in the population [2,3,4]. The composition of seasonal influenza vaccines has to be updated almost every each year according to the results of global influenza surveillance performed by World Health Organization. This annual updating process represents quite a burden for vaccine manufacturers and in case of pandemic outbreaks, this strategy is futile for the control of the first wave on the pandemic. M2e-specific IgG2a (BALB/c) and IgG2c (BL/6) offers stronger protection against influenza A virus challenged compared to IgG1 [15,19]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.